Tellus Therapeutics, a Dhuram, NC-based neonatal care company, raised $35M in Series A funding.
The round was led by Perceptive Xontogeny Venture Fund.
The company intends to use the funds for the development of TT-20 into clinical trials for white matter brain injury in preterm infants and its pipeline program.
Led by CEO Jason Kralic, Tellus Therapeutics is a neonatal care company developing safe and effective interventions for unmet needs of newborns. The company is translating science licensed from Duke University that originated in board-certified neonatologist Dr. Eric Benner’s research laboratory together with collaborator and Tellus scientific co-founder Dr. Simon Gregory. Dr. Benner’s work identified compounds in breast milk that induce the regeneration of myelin-producing oligodendrocytes and repair WMI in animal models of perinatal brain injury.
Tellus Therapeutics was seeded by Xontogeny in May 2021 to advance TT-20 through an FDA pre-IND meeting and to generate a clinical formulation suitable for newborn patients in the NICU. The Series A financing was closed following a positive FDA interaction and new formulation pharmacokinetic data in juvenile animals.
The company is led by Jason Kralic, Eric Benner (Co-Founder and acting Chief Scientific Officer) and Austin Schwartz (Vice President of Operations). Chris Garabedian and Fred Callori, Xontogeny Chief Executive Officer and Senior Vice President of Corporate Development, respectively, will continue to serve as Chairman and Member of the Tellus Board of Directors.
FinSMEs
13/12/2022